GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
galena biopharma (GALE) [hlAlert]

Rating:
Buy GALE
down 66.81 %

galena biopharma (GALE) rated Buy with price target $6 by Noble Financial

Posted on: Monday,  Feb 3, 2014  9:25 AM ET by Noble Financial

Noble Financial rated Buy galena biopharma (NASDAQ: GALE) on 02/03/2014, when the stock price was $4.49. Since
then, galena biopharma has lost 66.82% as of 01/21/2016's recent price of $1.49.
If you would have followed this Noble Financial's recommendation on GALE, you would have lost 66.81% of your investment in 717 days.

RXi Pharmaceuticals Corporation (RXi) is a discovery-stage biopharmaceutical company pursuing therapeutics based on ribonucleic acid interference (RNAi) for the treatment of human diseases. The Company is focused on internal research and development programs on certain inflammatory and metabolic diseases, and to pursue other therapeutic areas with potential partners. RXi commenced operations after CytRx Corporation contributed to the Company its portfolio of RNAi therapeutic assets, which consisted primarily of RNAi licenses and related intellectual property, and a nominal amount of equipment. As of December 31, 2008, the Company had not generated any revenues.

A clear and concise focus. Identifying the emerging small or micro cap company. Recognizing the entrepreneurial character and organizational commitment of its executives and employees. Observing unstoppable drive to exploit opportunities while tackling obstacles. Understanding the company's essential products, services and technologies. Following only those who deserve our attention.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/3/2014 9:25 AM Buy
None
4.49 6.00
as of 10/17/2014
1 Week up  8.77 %
1 Month down  -16.21 %
3 Months down  -27.90 %
1 YTD down  -58.57 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy